- Home
- ADAG vs EDAP Comparison
ADAG vs EDAP Comparison
Compare ADAG & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAG
- EDAP
- Stock Information
- Founded
- ADAG 2011
- EDAP 1979
- Country
- ADAG China
- EDAP France
- Employees
- ADAG N/A
- EDAP N/A
- Industry
- ADAG Biotechnology: Pharmaceutical Preparations
- EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- ADAG Health Care
- EDAP Health Care
- Exchange
- ADAG Nasdaq
- EDAP Nasdaq
- Market Cap
- ADAG 81.9M
- EDAP 88.7M
- IPO Year
- ADAG 2021
- EDAP 1997
- Fundamental
- Price
- ADAG $1.82
- EDAP $1.96
- Analyst Decision
- ADAG Strong Buy
- EDAP Strong Buy
- Analyst Count
- ADAG 1
- EDAP 2
- Target Price
- ADAG $8.00
- EDAP $11.75
- AVG Volume (30 Days)
- ADAG 38.1K
- EDAP 195.1K
- Earning Date
- ADAG 03-24-2025
- EDAP 03-27-2025
- Dividend Yield
- ADAG N/A
- EDAP N/A
- EPS Growth
- ADAG N/A
- EDAP N/A
- EPS
- ADAG N/A
- EDAP N/A
- Revenue
- ADAG $103,204.00
- EDAP $66,378,507.00
- Revenue This Year
- ADAG $6,488.89
- EDAP $16.46
- Revenue Next Year
- ADAG $57.50
- EDAP $14.30
- P/E Ratio
- ADAG N/A
- EDAP N/A
- Revenue Growth
- ADAG N/A
- EDAP 6.11
- 52 Week Low
- ADAG $1.33
- EDAP $1.90
- 52 Week High
- ADAG $3.58
- EDAP $8.50
- Technical
- Relative Strength Index (RSI)
- ADAG 50.71
- EDAP 32.54
- Support Level
- ADAG $1.39
- EDAP $1.96
- Resistance Level
- ADAG $1.83
- EDAP $2.57
- Average True Range (ATR)
- ADAG 0.18
- EDAP 0.27
- MACD
- ADAG -0.02
- EDAP -0.03
- Stochastic Oscillator
- ADAG 72.59
- EDAP 8.96
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
About EDAP EDAP TMS S.A.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.